Last results from Pfizer’s Covid-19 vaccine trial showed its shot had a 95 per cent success rate and two months of safety data, paving the way for the drugmaker to apply for an emergency US authorisation inside days, it said on Wednesday. Pfizer said it expected the United States FDA vaccine advisory committee to review and discuss the data in a public assembly that will likely be held in December.
The efficacy rate of the vaccine, developed by Pfizer and its German partner BioNTech, is the highest of any candidate in late-stage clinical trials so far. Global shares edged higher on Wednesday as Pfizer’s trial results more than offset concerns around the stubbornly high global infection rate. Pfizer shares rose 2.9 per cent when US markets opened while BioNTech jumped 4 per cent.
Pfizer has said it is exploring possibilities to make the Covid-19 vaccine to be had in India. “The firm remains dedicated to engaging with the government of India to advance its dialogue and explore opportunities to make the vaccine to be had to be used in India,” it said.
Pfizer and BioNTech said they plan to submit the data to other regulatory agencies around the globe.
V K Paul, member-health, NITI Aayog, and also the chairman of the committee on vaccine administration, said: “The vaccine must be kept in -70-degree Celsius temperature and will be difficult for countries to scale up… We are discussing this. The Pfizer vaccine is probably not to be had to us for a couple of months.” The government is examining all possibilities to extend cold-chain facilities in case Pfizer is procured.
Trade Standard has at all times strived tough to supply up-to-date information and observation on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and fixed feedback on how to make stronger our offering have only made our unravel and commitment to these ideals stronger. Even all through these difficult times arising out of Covid-19, we continue to remain dedicated to keeping you informed and up to date with credible news, authoritative views and incisive observation on topical issues of relevance.
We, then again, have a request.
As we battle the economic have an effect on of the pandemic, we need your fortify even more, in order that we will be able to continue to give you more quality satisfied. Our subscription mannequin has seen an encouraging response from many of you, who have subscribed to our online satisfied. More subscription to our online satisfied can only help us achieve the goals of offering you even better and more applicable satisfied. We imagine in free, reasonable and credible journalism. Your fortify through more subscriptions can help us practise the journalism to which we are dedicated.
Make stronger quality journalism and subscribe to Trade Standard.